Citations 4
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Pfister, David G. , Spencer, Sharon A., Adkins, Douglas, Birkeland, Andrew C. , Busse, Paul M., Durm, Greg Andrew , Fakhry, Carole , Galloway, Thomas J. , Geiger, J.L. , Gillison, Maura L. , Haddad, Robert I. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Pinto, Harlan A. , Price, Katharine A. , Rocco, James W. , Rodriguez, Cristina P. , Sher, David J. , Wang, He , Weinstein, Gregory S., Yom, Sue S. , Zhen, Weining, Darlow, Susan, Price, Katharine, Haddad, Robert , Yom, Sue S , Colevas, Alexander Dimitrios , Cmelak, Anthony J. , Adkins, Douglas, Brizel, David M. , Caudell, Jimmy J , Glastonbury, Christine M. , Hicks, Wesley L. , Juloori, Aditya , Kase, Michael, Mittal, Bharat B. , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Worden, Francis P. , Bruce, Justine Y. , Montgomery, Sarah E.
Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 2-11
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234.
Divi, Vasu , Cooper, Jay S., McHugh, Jonathan B. , Bell, Diana , Suntharalingam, Mohan, Raben, David, Kim, Harold E., Spencer, Sharon A., Laramore, George E. , Trotti, Andy, Foote, Robert L. , Schultz, Christopher J. , Zhang, Qiang , Harris, Jonathan , Harari, Paul M. , Sturgis, Erich M. , Cmelak, Anthony J. , Thorstad, Wade , Le, Quynh‐Thu , Holsinger, F. Christopher
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6011-6011
The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience.
Bar‐Ad, Voichita , Axelrod, Rita , Rosenthal, D.I., Trotti, Andy, Jones, Christopher U. , Song, Guobin , Foote, Robert L. , Raben, David, Shenouda, George , Spencer, Sharon A., Zhang, Qiang , Harari, Paul M. , Garden, Adam S. , Harris, Jonathan , Le, Quynh‐Thu
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6025-6025
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)
Divi, Vasu , Harari, Paul M. , Cooper, Jay S., McHugh, Jonathan B. , Bell, Diana , Cmelak, Anthony J. , Suntharalingam, Mohan, Raben, David, Kim, Harold , Spencer, Sharon A., Laramore, George E. , Trotti, Andy, Foote, Robert L. , Schultz, Christopher J. , Le, Quynh‐Thu , Harris, Jonathan , Sturgis, Erich M. , Thorstad, Wade , Zhang, Qiang , Holsinger, F. Christopher , Kim, Harold E , Le, Quynh-Thu
Cancer | July 15, 2016 | Volume: 122 | Issue: 22 | Pages: 3464-3471
BACKGROUNDProspective quality metrics for neck dissection have not been established for patients with head and neck squamous cell carcinoma. The purpose of this study was to investigate the association between lymph node counts from neck dissection, local‐regional recurrence, and overall survival.METHODSThe number of lymph nodes counted from neck dissection in patients treated in 2 NRG Oncology trials (Radiation Therapy Oncology Group [RTOG] 9501 and RTOG 0234) was evaluated for its prognostic impact on overall survival with a multivariate Cox model adjusted for demographic, tumor, and lymph node data and stratified by the postoperative treatment group.RESULTSFive hundred seventy‐two patients were analyzed at a median follow‐up of 8 years. Ninety‐eight percent of the patients were pathologically N+. The median numbers of lymph nodes recorded on the left and right sides were 24 and 25, respectively. The identification of fewer than 18 nodes was associated with worse overall survival in comparison with 18 or more nodes (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.09‐1.74; P = .007). The difference appeared to be driven by local‐regional failure (HR, 1.46; 95% CI, 1.02‐2.08; P = .04) but not by distant metastases (HR, 1.08; 95% CI, 0.77‐1.53; P = .65). When the analysis was limited to NRG Oncology RTOG 0234 patients, adding the p16 status to the model did not affect the HR for dissected nodes, and the effect of nodes did not differ with the p16 status.CONCLUSIONSThe removal and identification of 18 or more lymph nodes was associated with improved overall survival and lower rates of local‐regional failure, and this should be further evaluated as a measure of quality in neck dissections for mucosal squamous cell carcinoma. Cancer 2016;122:3464–71. © 2016 American Cancer Society.